Key result
Novel drugs targeting genetic variants including SGLT2i and ARNI show promising heart failure benefits.
Why the study?
Traditional treatment methods for chronic heart failure are rapidly evolving with the emergence of novel drugs targeting genetic mutations.
This review summarizes the mechanisms, clinical trial data, and real-world applications of novel drugs targeting genetic variants for chronic heart failure.
May guide HF therapy via genetic profiling; extends evidence to precision applications of SGLT2i and ARNI.
Chronic heart failure (HF) is a common and frequently occurring disease worldwide, and its traditional treatment methods are undergoing earth-shaking changes. This study analyzes novel drugs targeting genetic mutations that have been launched in recent years, such as sodium-glucose co-transporter 2 inhibitors, angiotensin receptor neprilysin inhibitors, soluble guanylate cyclase, cardiac myosin activators, potassium channel openers, and vasopressin receptor antagonists, compares the drug action mechanisms, key clinical trial data in the research, and the application of real-world research, and discusses the clinical value and existing problems of new drugs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Heart failure. Novel drugs targeting genetic variants (SGLT2i, ARNI, vericiguat) vs. Traditional treatments was evaluated. Novel drugs targeting genetic variants, including SGLT2 inhibitors and ARNIs, significantly improve heart failure prognosis, though real-world application is limited by high costs and adverse effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: